Stocks and InvestingStocks and Investing
Tue, October 20, 2020
Mon, October 19, 2020
Fri, October 16, 2020
Thu, October 15, 2020

Robyn Karnauskas Maintained (VRTX) at Strong Buy with Decreased Target to $305 on, Oct 15th, 2020


Published on 2024-10-27 14:22:28 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Decreased Target from $330 to $305 on, Oct 15th, 2020.

Robyn has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $281 on, Tuesday, October 13th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $276 on, Sunday, October 4th, 2020


These are the ratings of the 6 analyists that currently disagree with Robyn


  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $305 on, Friday, July 31st, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $309 on, Friday, July 31st, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $328 on, Monday, July 20th, 2020
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020